In univariate analysis, low EZH2 IHC expression was significantly associated with superior OS (p = 0.035, OS = 77% at 3 years versus 35%) and PFS (p = 0.02, PFS = 77% at 3 years versus 29%) in ABC patients treated with R-chemotherapy (Figure 4A, 4B). Here, EZH2 is linked to aneurysmal bone cyst.